|
1
|
Habermann TM, Weller EA, Morrison VA, et
al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab
in older patients with diffuse large B-cell lymphoma. J Clin Oncol.
24:3121–3127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alizadeh AA, Eisen MB, Davis RE, et al:
Distinct types of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosenwald A, Wright G, Chan WC, et al: The
use of molecular profiling to predict survival after chemotherapy
for diffuse large-B-cell lymphoma. N Engl J Med. 346:1937–1947.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ninan MJ, Wadhwa PD and Gupta P:
Prognostication of diffuse large B-cell lymphoma in the rituximab
era. Leuk Lymphoma. 52:360–373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim VN, Han J and Siomi MC: Biogenesis of
small RNAs in animals. Nat Rev Mol Cell Biol. 10:126–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davis BN and Hata A: microRNA in cancer:
the involvement of aberrant microRNA biogenesis regulatory
pathways. Genes Cancer. 1:1100–1114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hobert O: Common logic of transcription
factor and microRNA action. Trends Biochem Sci. 29:462–468. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alencar AJ, Malumbres R, Kozloski GA, et
al: MicroRNAs are independent predictors of outcome in diffuse
large B-cell lymphoma patients treated with R-CHOP. Clin Cancer
Res. 17:4125–4135. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA, Ferracin M, Cimmino A, et al: A
microRNA signature associated with prognosis and progression in
chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marcucci G, Radmacher MD, Maharry K, et
al: MicroRNA expression in cytogenetically normal acute myeloid
leukemia. N Engl J Med. 358:1919–1928. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Montes-Moreno S, Martinez N,
Sanchez-Espiridion B, et al: miRNA expression in diffuse large
B-cell lymphoma treated with chemoimmunotherapy. Blood.
118:1034–1040. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schwind S, Maharry K, Radmacher MD, et al:
Prognostic significance of expression of a single microRNA,
miR-181a, in cytogenetically normal acute myeloid leukemia: a
Cancer and Leukemia Group B study. J Clin Oncol. 28:5257–5264.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yanaihara N, Caplen N, Bowman E, et al:
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang CJ, Chao CH, Xia W, et al: p53
regulates epithelial-mesenchymal transition and stem cell
properties through modulating miRNAs. Nat Cell Biol. 13:317–323.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Papadopoulou V, Postigo A, Sanchez-Tillo
E, Porter AC and Wagner SD: ZEB1 and CtBP form a repressive complex
at a distal promoter element of the BCL6 locus. Biochem J.
427:541–550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lossos IS, Jones CD, Warnke R, et al:
Expression of a single gene, BCL-6, strongly predicts survival in
patients with diffuse large B-cell lymphoma. Blood. 98:945–951.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shimono Y, Zabala M, Cho RW, et al:
Downregulation of miRNA-200c links breast cancer stem cells with
normal stem cells. Cell. 138:592–603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wellner U, Schubert J, Burk UC, et al: The
EMT-activator ZEB1 promotes tumorigenicity by repressing
stemness-inhibiting microRNAs. Nat Cell Biol. 11:1487–1495. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Korpal M, Ell BJ, Buffa FM, et al: Direct
targeting of Sec23a by miR-200s influences cancer cell secretome
and promotes metastatic colonization. Nat Med. 17:1101–1108. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hamano R, Miyata H, Yamasaki M, et al:
Overexpression of miR-200c induces chemoresistance in esophageal
cancers mediated through activation of the Akt signaling pathway.
Clin Cancer Res. 17:3029–3038. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu LZ, Zhou XD, Qian G, Shi X, Fang J and
Jiang BH: AKT1 amplification regulates cisplatin resistance in
human lung cancer cells through the mammalian target of
rapamycin/p70S6K1 pathway. Cancer Res. 67:6325–6332. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thompson JE and Thompson CB: Putting the
rap on Akt. J Clin Oncol. 22:4217–4226. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Uddin S, Hussain AR, Siraj AK, et al: Role
of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large
B-cell lymphoma survival. Blood. 108:4178–4186. 2006.
|
|
27
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hans CP, Weisenburger DD, Greiner TC, et
al: Confirmation of the molecular classification of diffuse large
B-cell lymphoma by immunohistochemistry using a tissue microarray.
Blood. 103:275–282. 2004. View Article : Google Scholar : PubMed/NCBI
|
